Trial Profile
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Germ cell cancer
- Focus Therapeutic Use
- 25 Feb 2021 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 20 Apr 2020 Planned End Date changed from 1 Mar 2019 to 1 Jun 2020.